Study aid only. Verify against current guidelines before clinical use.
Board-Prep Notes

Disease-site reference notes for boards review.

Iron overload (hemochromatosis)

Benign Hematology
Iron overload (hemochromatosis)

Hereditary hemochromatosis (HH)

Diagram of hereditary hemochromatosis: HFE mutation lowers hepcidin, causing unrestricted gut iron absorption and organ iron loading, with HFE genotypes ranked by phenotype severity and the organs affected.
HFE hemochromatosis: genotype, mechanism, and target organs. Tap to enlarge.
  • Most common: HFE gene mutations (chromosome 6p):
    • C282Y homozygotes: classic phenotype (~80% of European HH cases). Northern European Caucasian (1:200 to 400 prevalence).
    • C282Y/H63D compound heterozygotes: milder phenotype.
    • H63D homozygotes: usually no phenotype unless cofactors (alcohol, viral hepatitis, NAFLD).
  • Pathophysiology: HFE mutations → ↓ hepcidin → unrestricted iron absorption from gut → progressive iron accumulation in liver, heart, pancreas, joints, pituitary, skin.
  • Penetrance variable: only ~30% of homozygotes develop overt disease (cofactors: male sex, alcohol, viral hepatitis, NAFLD).

Clinical features

  • Classic "bronze diabetes": hyperpigmentation + diabetes + cirrhosis (late finding).
  • Common manifestations:
    • Fatigue, malaise (often the only symptom).
    • Hepatic: elevated LFTs, hepatomegaly, cirrhosis, HCC (~200 × ↑ risk in cirrhosis).
    • Cardiac: cardiomyopathy (restrictive then dilated), arrhythmias, conduction disease.
    • Endocrine: diabetes (pancreatic deposition), hypogonadism (pituitary), hypothyroidism, secondary hypopituitarism, adrenal insufficiency.
    • Arthropathy: MCP joints (especially 2nd and 3rd), wrists, ankles. CPPD ("pseudogout").
    • Skin: bronze hyperpigmentation (chronic; melanin + hemosiderin).
    • Susceptibility to certain infections: Vibrio vulnificus (raw seafood), Yersinia, Listeria.

Diagnosis

Two-column chart for hereditary hemochromatosis: diagnose with fasting transferrin saturation and ferritin against sex-specific cutoffs, HFE genotyping and MRI of liver and heart; then treat with weekly phlebotomy to a ferritin of 50 to 100 ng/mL, maintenance every 2 to 4 months, and follow-up measures.
Hereditary hemochromatosis: from suspicion to phlebotomy and follow-up. Tap to enlarge.
  • Screening: not population-based; consider with family history, suggestive labs, or end-organ damage.
  • Iron studies: fasting TSAT >45% (women) or >50% (men) + ferritin >200 (women) or >300 (men) → suggestive.
  • Genetic testing: HFE C282Y, H63D.
  • Liver assessment: MRI R2*/T2* for liver iron concentration (LIC), non-invasive, replaces liver biopsy in most cases. Biopsy if diagnosis unclear or fibrosis assessment needed.
  • Cardiac assessment: MRI T2* if cardiac involvement suspected.

Treatment of HH

  • Therapeutic phlebotomy: mainstay. 500 mL weekly (~250 mg iron each) until ferritin 50 to 100 ng/mL or borderline anemia. Then maintenance q2 to 4 months to keep ferritin 50 to 100.
  • Pre-cirrhotic patients with adequate phlebotomy: normal life expectancy.
  • Iron chelation (deferoxamine, deferasirox, deferiprone): for those who cannot tolerate phlebotomy or have transfusion-dependent overload.
  • Avoid exogenous iron, vitamin C supplements (can ↑ iron absorption and toxicity), and uncooked seafood/shellfish (Vibrio risk).
  • HCC screening if cirrhosis: ultrasound ± AFP q6 months.
  • Family screening: first-degree relatives of HH patients should have iron studies + HFE genotyping.

Other iron overload disorders

Three-column panel sorting iron overload that is not HFE hemochromatosis by its clue: non-HFE hereditary forms (juvenile HH from HJV type 2A or HAMP type 2B, TFR2 type 3, autosomal dominant ferroportin disease SLC40A1 type 4), overload with anemia (aceruloplasminemia with neurologic signs and low TSAT despite high ferritin; atransferrinemia with severe microcytic anemia), and secondary or dietary overload (chronic transfusions, ineffective erythropoiesis with suppressed hepcidin, African iron overload).
Iron overload beyond HFE: non-HFE hereditary forms, overload with anemia, and secondary or dietary overload. Tap to enlarge.
  • Non-HFE hereditary hemochromatosis (rare):
    • HJV (hemojuvelin): juvenile HH type 2A; severe early-onset cardiac/endocrine.
    • HAMP (hepcidin): juvenile HH type 2B.
    • TFR2 (transferrin receptor 2): HH type 3.
    • SLC40A1 (ferroportin disease, autosomal dominant): HH type 4; loss-of-function causes macrophage iron loading; gain-of-function gives the classic phenotype.
  • Aceruloplasminemia: CP gene; iron overload + neurologic symptoms (ataxia, dementia, retinal degeneration); low TSAT (low serum iron, mild microcytic anemia) with ↑ ferritin (key distinguishing feature).
  • Atransferrinemia: rare; severe microcytic anemia + iron overload (paradoxical).
  • African iron overload: dietary (traditional brewing in iron pots) + genetic predisposition (SLC40A1 polymorphisms).
  • Secondary iron overload: chronic transfusions (thalassemia major, SCD, MDS, aplastic anemia, chemotherapy); ineffective erythropoiesis (suppressed hepcidin in thalassemia, MDS-RS).
  • Liver disease: NAFLD, alcoholic liver disease, chronic hepatitis C, can cause moderate ferritin elevation without true iron overload.

Iron overload from chronic transfusion

  • Each unit of pRBC contains ~200 to 250 mg iron. There is no mechanism to excrete iron, so it deposits in organs. Iron accumulation becomes significant after ~15 to 20 units.
  • Organ deposition: liver (fibrosis, cirrhosis, HCC); heart (heart failure, arrhythmia); endocrine (hypogonadotropic hypogonadism, decreased bone mineral density, diabetes, hypothyroidism, hypoparathyroidism, growth failure).
  • When to start chelation: once ferritin >1000 µg/L, OR after the first ~10 to 20 transfusions, OR after approximately 20 units of blood. Also for LIC >7 mg Fe/g dry weight.
  • Monitoring: serum ferritin every 3 months (rough proxy); liver MRI (R2* or T2*) for LIC if ferritin >1000 ng/mL; In transfusion-dependent thalassemia, obtain scheduled cardiac T2* MRI (typically from age 8 to 10), frequency set by cardiac iron burden; cardiac iron can be high despite normal LVEF and near-normal liver iron. Reserving cardiac MRI for high-risk patients applies to sickle cell disease. Liver and cardiac iron by MRI are the most accurate stores measurements.

Chelation targets

Iron chelation targetsTransfusional iron overload
ParameterAbnormal / start chelationGoal on chelation
Serum ferritin>1000 µg/L (or ~20 units transfused)<1000 to 1500 µg/L
Liver iron (LIC, MRI R2*/T2*)>7 mg Fe/g dry weight (normal <1.8)Maintain 2 to 5 mg Fe/g dry weight
Cardiac T2*<20 ms (↑ heart failure risk)Keep >20 ms

Iron chelators

Three-column comparison of deferoxamine, deferasirox and deferiprone showing route and schedule, signature toxicity (oto/ophthalmotoxicity, renal and hepatic, agranulocytosis), other toxicities and monitoring, with combination therapy and general monitoring below.
Iron chelators compared: route, signature toxicity, and monitoring. Tap to enlarge.
  • Deferoxamine (Desferal): older parenteral chelator; SC 8 to 12 hr infusion 5 to 7 nights/week or IV. Toxicities: ototoxicity (high-frequency hearing loss), ophthalmotoxicity (cataracts, retinopathy), growth retardation in children, infusion-site reactions. Annual audiology/ophthalmology screen. Yersinia infection risk.
  • Deferasirox (Exjade, Jadenu): oral once daily; standard for chronic transfusional overload. Toxicities: renal (Cr ↑, possible Fanconi syndrome), hepatic (LFT elevation, rarely failure), GI; rash, cytopenias. Deferasirox: monitor renal function/tubular markers weekly during the first month after start or dose change, then at least monthly; check AST, ALT, and bilirubin every 2 weeks during the first month, then at least monthly.
  • Deferiprone (Ferriprox): oral 3 times/day; combined with deferoxamine for cardiac iron. Toxicity: agranulocytosis (~1 to 2%); monitor ANC before starting, weekly for the first 6 months, every 2 weeks for months 6 to 12, then every 2 to 4 weeks thereafter (per current Ferriprox label); arthropathy, GI.
  • Combination therapy: deferoxamine + deferiprone for severe cardiac iron (better cardiac penetration).
  • Monitoring: ferritin q3 months; LIC by MRI R2*/T2* annually; cardiac T2* annually if cardiac involvement; renal/hepatic per drug.

High yield

  • HFE C282Y homozygote = most common HH; variable penetrance.
  • Therapeutic phlebotomy is the mainstay for HFE-HH; normal life expectancy if pre-cirrhotic.
  • Avoid Vibrio vulnificus (raw oysters), can be fatal in iron overload.
  • Cirrhosis + HH = ~200 × HCC risk; surveil with ultrasound/AFP q6 months.
  • Aceruloplasminemia: iron overload + neurologic findings + low TSAT with high ferritin (distinct).
  • Transfusional overload: chelate when ferritin >1000 or LIC >7 mg Fe/g dry weight; keep cardiac T2* >20 ms.
  • Chelator toxicities: deferoxamine = oto/ophthalmotoxicity; deferasirox = renal/hepatic; deferiprone = agranulocytosis (weekly CBC).
Veli Bakalov MD, Board Review Notes 2026